BEAM Quote, Financials, Valuation and Earnings

Electromed has a net margin of -1462.79% compared to Beam Therapeutics's net margin of 12.11%. Beam Therapeutics's return on equity of -43.86% beat Electromed's return on equity of 15.91%.

Beam Therapeutics has a consensus price target of $45.00, signalling upside risk potential of 158.47%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 66.14%. Given that Beam Therapeutics has higher upside potential than Electromed, analysts believe Beam Therapeutics is more attractive than Electromed.

Beam Therapeutics has a beta of 2.349, which suggesting that the stock is 134.943% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than Electromed quarterly revenues of $16.3M. Beam Therapeutics's net income of -$109.3M is lower than Electromed's net income of $2M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 29.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 22.97x versus 3.34x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics has a net margin of -1462.79% compared to Beam Therapeutics's net margin of -687.61%. Beam Therapeutics's return on equity of -43.86% beat Intellia Therapeutics's return on equity of -56.9%.

Beam Therapeutics has a consensus price target of $45.00, signalling upside risk potential of 158.47%. On the other hand Intellia Therapeutics has an analysts' consensus of $40.56 which suggests that it could grow by 399.45%. Given that Intellia Therapeutics has higher upside potential than Beam Therapeutics, analysts believe Intellia Therapeutics is more attractive than Beam Therapeutics.

Beam Therapeutics has a beta of 2.349, which suggesting that the stock is 134.943% more volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.332, suggesting its more volatile than the S&P 500 by 133.227%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Beam Therapeutics's net income of -$109.3M is higher than Intellia Therapeutics's net income of -$114.3M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 22.97x versus 17.97x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -1462.79% compared to Beam Therapeutics's net margin of -60.08%. Beam Therapeutics's return on equity of -43.86% beat Sarepta Therapeutics's return on equity of -20.94%.

Beam Therapeutics has a consensus price target of $45.00, signalling upside risk potential of 158.47%. On the other hand Sarepta Therapeutics has an analysts' consensus of $96.72 which suggests that it could grow by 166.66%. Given that Sarepta Therapeutics has higher upside potential than Beam Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Beam Therapeutics.

Beam Therapeutics has a beta of 2.349, which suggesting that the stock is 134.943% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Beam Therapeutics's net income of -$109.3M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 22.97x versus 1.80x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -1462.79% compared to Beam Therapeutics's net margin of -93.48%. Beam Therapeutics's return on equity of -43.86% beat Viatris's return on equity of -20.24%.

Beam Therapeutics has a consensus price target of $45.00, signalling upside risk potential of 158.47%. On the other hand Viatris has an analysts' consensus of $11.7471 which suggests that it could grow by 33.95%. Given that Beam Therapeutics has higher upside potential than Viatris, analysts believe Beam Therapeutics is more attractive than Viatris.

Beam Therapeutics has a beta of 2.349, which suggesting that the stock is 134.943% more volatile than S&P 500. In comparison Viatris has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.265%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.47% to investors and pays a quarterly dividend of $0.12 per share. Beam Therapeutics pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than Viatris quarterly revenues of $3.3B. Beam Therapeutics's net income of -$109.3M is higher than Viatris's net income of -$3B. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 22.97x versus 0.73x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.